Yu Xiao (He/Him)

Senior Researcher, Zhongnan Hospital of Wuhan University
  • China

Mevalonate pathway inhibition reduces bladder cancer metastasis by modulating RhoB protein stability and integrin β1 localization

Activating the mevalonate (MVA) pathway increases bladder cancer (BLCA) spread. High MVA enzyme levels predict worse outcomes. Drugs like zoledronic acid or simvastatin blocking this pathway reduce cancer cell migration by affecting the protein RhoB. Targeting the MVA pathway could help treat BLCA.
Go to the profile of Gang  Wang +3
Gang Wang and 3 others
Nov 09, 2024